INTECH Investment Management’s Celldex Therapeutics CLDX Stock Holding History

INTECH Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$797K	Buy	21,411 +56	+0.3%	+$1.81K	0.01%	1138
2026 Q1	$677K	Sell	21,355 -12,144	-36%	-$331K	0.01%	1190
2025 Q4	$910K	Buy	33,499 +2,608	+8%	+$68.7K	0.01%	1181
2025 Q3	$799K	Sell	30,891 -11,009	-26%	-$255K	0.01%	1313
2025 Q2	$853K	Buy	41,900 +7,679	+22%	+$149K	0.01%	1289
2025 Q1	$621K	Buy	34,221 +286	+0.8%	+$6.39K	0.01%	1495
2024 Q4	$858K	Buy	33,935 +8,303	+32%	+$226K	0.01%	1244
2024 Q3	$871K	Buy	+25,632	New	+$977K	0.01%	892

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

INTECH Investment Management's CLDX Position: Q2 2026 in Review

INTECH Investment Management increased its Celldex Therapeutics (CLDX) stake by 0.26% in Q2 2026, buying an estimated $1.81K and bringing the position to 21,411 shares worth $797K. The position accounts for 0.01% of the portfolio, ranked #1138.

INTECH Investment Management first reported a position in CLDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $910K in Q4 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

INTECH Investment Management held 21,411 shares of Celldex Therapeutics worth $797K as of Q2 2026.
INTECH Investment Management bought 56 Celldex Therapeutics shares in Q2 2026, an estimated $1.81K.
Celldex Therapeutics made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1138 holding.
INTECH Investment Management first reported a position in Celldex Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Celldex Therapeutics position peaked at $910K in Q4 2025.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.